DB
TRAW icon

Danske Bank’s Traws Pharma TRAW Stock Holding History

Danske Bank’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7
Closed -$41 – 1677
2024
Q3 		$41 Buy
+7
New +$64 ﹤0.01% 1483

Other funds holding TRAW

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Danske Bank's TRAW Position: Q4 2024 in Review

Danske Bank sold out of Traws Pharma (TRAW) in Q4 2024, closing a stake of 7 shares — an estimated $41 sold.

Danske Bank first reported a position in TRAW in Q3 2024 and held it in 1 quarter. The position peaked at $41 in Q3 2024. 19 funds tracked by Wall St. Rank hold TRAW as of Q4 2024.

  • Danske Bank reported no remaining Traws Pharma position as of Q4 2024 after selling out during the quarter.
  • Danske Bank sold 7 Traws Pharma shares in Q4 2024, an estimated $41.
  • Danske Bank first reported a position in Traws Pharma in Q3 2024 and held it in 1 quarter.
  • Danske Bank's Traws Pharma position peaked at $41 in Q3 2024.
  • 19 funds tracked by Wall St. Rank held Traws Pharma as of Q4 2024.

Based on Danske Bank's 13F filing for Q4 2024, filed 18 Mar 2026.